Key Takeaways
- Sharp Q2 rebound, but margin pain persists: Revenue jumped 148% QoQ as the non-ARV pivot took hold, yet EBITDA margins remain under pressure from low API pricing and high-cost inventory.
- The ARV detox is complete: ARV contribution collapsed from 40–50% historically to just 8% in Q2, and management now treats any ARV revenue as a bonus, not a dependency.
- Ibuprofen is the new volume engine: The recently commissioned facility is gaining market share month-on-month and has received its European CEP, opening the door to regulated-market exports in 6–8 months.
- Sitagliptin launch shows early traction: The anti-diabetic molecule is already shipping to Spain and ROW markets, with the US patent opening in late 2024, setting up a multi-year volume runway.
- What to watch next quarter: Whether gross margins begin their promised climb toward the 37–38% range in Q4, the pace of ibuprofen capacity fill, and any ARV tender surprise that could act as a margin kicker.
The Non-ARV Pivot
- ARV dependency eliminated: ARV contribution fell from 40–50% of revenue historically to 8% in Q2 FY23, driven by severe pricing and demand disruption that slashed capacity utilization. Management now explicitly treats any ARV revenue as opportunistic upside.
- Non-ARV products recouped lost ground: The company launched products in new therapeutic categories and increased market share of non-ARV products quickly, almost fully recouping the topline lost from the ARV decline.
- Volume tells the real story: Revenue degrew 8.7% YoY, but volumes grew 30–35% YoY because of the addition of high-volume ibuprofen, which carries single-digit or sub-single-digit margins, so its top-line contribution is small relative to volume.
- Anti-diabetic ambition: The anti-diabetic segment, led by sitagliptin, is expected to become a flagship, with the entire segment targeted to contribute 25–30% of topline over the long term.
Potluri: "So what we are considering ARV is as bonus rather than having them having us depend on them."
Ibuprofen: The Volume Bet
- Facility ramping well: The recently commissioned ibuprofen facility is growing at a healthy pace month-on-month and has taken significant market share in both domestic and export markets.
- European access unlocked: The company received a CEP for ibuprofen in Q2 FY23, and is already in qualification with many European customers; validation and filing is expected to take approximately 6–8 months before commercial exports begin.
- Pricing near a floor: Ibuprofen prices are still dropping, but management feels prices have more or less bottomed out and expects them to stay around current levels or show a slight upward trend based on market correction.
- Peak revenue potential: The ibuprofen facility carries a peak revenue potential of ₹600–700 crores, based on current pricing.
- FY24 growth driver: Ibuprofen is the major growth driver for FY24, with the aim to increase capacity utilization further and become one of the largest manufacturers of ibuprofen globally.
Potluri: "So again, so at some point of time, it has to bottom out, right. So we feel that it's more or less almost bottomed out actually at this point in time."
Sitagliptin & the Anti-Diabetic Opportunity
- Launch traction: Sitagliptin has seen significant uptake since launch, with a major portion exported to Spain for the JV partner who launched in Europe. Plans are in place to enter domestic markets.
- Patent-constrained for now: Volumes are currently limited because only Spain, domestic, and a few ROW markets are open on the patent side; the US patent opens in late 2024, after which volumes are expected to be much higher.
- Long-term anchor: The anti-diabetic segment as a whole is expected to contribute 25–30% of topline over the long term, making it one of the flagship therapeutic categories for the company.
Margins: The Recovery Path
- What crushed margins: Lower API pricing, high-cost inventory, and negative operating leverage from the fall in ARV demand all hit EBITDA margins and PAT. Gross margin depletion reflects both high-cost inventory still in the system and severe market pricing pressure as supply exceeds demand.
- High-cost inventory nearly done: High-cost inventory was almost fully destocked in Q2 FY23, and input cost pressure decreased during the quarter. Management expects the high-cost inventory overhang to be mostly gone by Q4 FY23, though Q3 may still face some challenges.
- The margin ramp: Management anticipates margins bouncing back to the 15–18% range from Q4 onwards, with a sustainable 15–20% EBITDA margin based on the current product profile, excluding any ARV tender upside.
- Normalized gross margin target: Over the next two years, normalized gross margins are expected to be around 30–35%, because the focus is on top-line growth with high-volume products; FY22 margins were an outlier due to COVID projects.
- Cost discipline: Costs below gross margin (employee, power, etc.) are expected to increase only 10–15% over the next two years, providing operating leverage as revenue scales.
Potluri: "15% to 20% for sure, we can sustain from Q4 onwards. I think we will sustain even earlier. Again, definitely depends on the product mix and suddenly, we get another tender. So that is bonus."
Balance Sheet & Working Capital
- Receivables build is structural: Trade receivables increased in the last six months because top-line growth is now driven by the company's own product mix rather than CMO business, requiring more working capital for procurement and sales on both domestic and export sides.
- Molnupiravir inventory overhang: Approximately ₹50–55 crores of WIP inventory for a COVID product (Molnupiravir) is not moving because the pandemic spread curtailed; the company is trying to liquidate it in ROW markets where it has an innovator license.
- Inventory levels to stay elevated: Old inventory is expected to move out over the next 2–3 quarters, but high-volume products will keep inventory levels elevated compared to previous levels.
- No major capex ahead: No significant capex is planned for next year; the focus is on consolidation and filling existing capacity with more products, with only small environmental capex planned.
JV & VKT Updates
- JV operations are back-end loaded: No operations occurred in the JV during the period because the JV is used to file DMFs; sales to the JV partner are reconciled quarterly and squared off annually, so activity appears in Q4. The profit-sharing ratio is 45:55 with the Chemo JV globally, applying only on third-party sales.
- VKT facility gaining momentum: Commercial launches at VKT have occurred, with repeat orders and continuous monthly forecasts being received. A couple of big CMO contracts at VKT have been closed and executed, expected to bring the facility to approximately 80% occupancy with revenues starting from June onwards.
- Ranitidine ANDA on hold: The Ranitidine ANDA at VKT remains on standstill and is expected to take 1–2 years.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 revenue growth | ~10% growth over last year (~₹520–570 crores), despite Q1 weakness | FY23 full year |
| FY24 revenue growth | 20% growth, driven primarily by ibuprofen ramp | FY24 |
| EBITDA margin recovery | 15–18% range | From Q4 FY23 onwards |
| Sustainable EBITDA margin | 15–20%, based on current product profile, excluding ARV upside | From Q4 FY23 onwards |
| Gross margin recovery | 37–38% range | From Q4 FY23 onwards |
| Normalized gross margin | 30–35% range, as focus shifts to high-volume products | Over next two years |
| Ibuprofen European exports | First commercial shipments to European clients post-CEP qualification | 6–8 months |
| Sitagliptin US volumes | Material volume ramp-up when US patent opens | Late 2024 |
| VKT facility utilization | ~80% occupancy, with revenues starting | From June onwards |
| Capex | No significant capex; only small environmental spend | FY24 |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹159.4 cr, up 148% QoQ; H1 FY23 at ₹223.8 cr |
| API segment revenue | ₹159.1 cr, 99.8% of consolidated revenue |
| EBITDA margin | Turned positive in Q2 FY23 after negative in Q1; Q4 FY23 expected at 15–18% |
| Gross margin | Pressured by high-cost inventory and pricing; destocking largely complete, normalization expected from Q4 FY23 |
| Profit after tax | Impacted by lower API pricing, high-cost inventory, and negative operating leverage |
| FY23 revenue growth guidance | ~10% growth from last year, implying ~₹520–570 cr (per an analyst's math) |
| FY24 revenue growth outlook | 20% growth projected |
| Anti-diabetic revenue share | ~58% of API revenue in Q2 FY23; expected to normalize to 25–30% of topline going forward |
| ARV revenue share | ~8% of API revenue, down from 40–50% historically |
| Ibuprofen capacity utilization | ~50% of initial installed capacity, or 150 metric tons per month out of 300 |
| Ibuprofen peak revenue potential | ₹600–700 cr at full capacity utilization with process improvements |
| Volume growth (YoY) | 30–35%, driven by ibuprofen ramp-up; revenue degrew 8.7% YoY due to price correction and product mix |
| Inventory | ₹261.6 cr total as of Sep 2022; ₹210 cr in WIP and raw materials, ₹50 cr in finished goods |
| Molnupiravir inventory in WIP | ~₹50–55 cr, company working to liquidate in ROW markets |
| Long-term debt | ₹170 cr; short-term debt ~₹90 cr; average cost of borrowing below 8% |
| R&D spend | ~2% of revenue in Q2 FY23; ~3–3.5% in H1 FY23 |